T. Stiewe

Resistance patterns in drug-adapted cancer cell lines reflect complex evolution in clinical tumors

This study identifies drug-resistant sublines of TNBC cell lines and finds that resistance mechanisms are unique and unpredictable, suggesting new potential drug targets.

Functional diversity of the TP53 mutome revealed by saturating CRISPR mutagenesis

This study uses CRISPR mutagenesis to analyze the functional impact of TP53 mutations across 9,225 variants, revealing their effects on tumor cell fitness and metastasis.

Haptoglobin buffers lipopolysaccharides to safeguard against aberrant NFκB activation

This study shows haptoglobin binds and buffers lipopolysaccharides to delay NFκB activation in macrophages, suggesting its role in preventing aberrant inflammation.

Peptide-mediated inhibition of the transcriptional regulator Elongin BC induces apoptosis in cancer cells

The paper develops a peptide inhibitor targeting the Elongin BC dimer, showing reduced cancer cell viability and increased apoptosis by blocking its interaction partners.

Robustness of the autophagy pathway to somatic copy number losses

This study shows that the autophagy pathway remains robust despite copy number losses of key genes in cancer cells, as evidenced by minimal metabolic vulnerability and lack of p62 accumulation.

IRF4 deficiency vulnerates B cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity

This study shows IRF4 deficiency leads to B cell leukemia via Jak3 mutations that increase IL-7 sensitivity, and JAK inhibition improves survival in a mouse model.

Single cell RNA-seq uncovers the nuclear decoy lincRNA PIRAT as a regulator of systemic monocyte immunity during COVID-19

The paper identifies PIRAT, a lncRNA regulating monocyte immunity in COVID-19 via PU.1 feedback, and shows its role in alarmin production.

Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting

The paper investigates drug-induced heterogeneity in cancer cell lines and identifies biomarkers for acquired resistance to YM155.